Introduction
CMV infection remains one of the biggest problems in patients after SCT and is strongly associated with immunodeficiency after transplantation. [1] [2] [3] [4] [5] [6] Since therapy of established disease is often inadequate, two strategies have been developed to prevent disease, universal prophylaxis and pre-emptive therapy. Universal prophylaxis is aimed at treating all patients at risk of disease on the basis of pre-transplant factors, whereas in pre-emptive therapy antiviral treatment is limited to patients with laboratory evidence of viral replication. 7 The strategy of initiation of antiviral therapy based on the results of sensitive methods such as the shell vial culture assay, the pp65 antigenemia assay, qualitative and quantitative PCR for DNA and detection of mRNA (NASBA) has improved overall survival. 8 However, both strategies result in significant over-treatment, that is treatment of patients who would not develop CMV disease. Furthermore, treatment with the currently available antiviral agents is associated with side effects, a risk of development of antiviral resistance and late onset of CMV disease. [9] [10] [11] According to the results of previous studies, 30-65% of patients who have undergone SCT might receive antiviral treatment unnecessarily. 9, 12 It has been shown in several studies that restoration of specific T cell-mediated immunity to CMV is associated with a low risk of subsequent CMV disease. [13] [14] [15] [16] The aim of the present prospective study was to use assays for monitoring of CMV-specific immunity after day 100 to target antiviral therapy to patients at the highest risk of developing CMV disease.
Materials and methods

Study patients
Fifty-eight patients, who were either CMV-seropositive or who had CMV-seropositive donors, and who were to undergo allogeneic SCT between November 2003 and March 2006 at Karolinska University Hospital, were prospectively included in the present study. The study was approved by the Ethics Committee of the Karolinska Institutet. Patients' characteristics are shown in Table 1 . The median age of donors was 40.2 (range: 0-71) years. The average amount of progenitor cells infused to patients was 8.91 Â 10 6 CD34 þ /kg body weight. None of the patients received an in vitro T cell-depleted graft.
Blood samples from the patients were obtained at 3, 4.5 and 6 months after SCT. PBMCs were isolated from heparintreated whole blood by density gradient centrifugation on Lymphoprep (Nycomed, Oslo, Norway). The cells were washed twice in PBS (GIBCO BRL, Grand Island, NY, USA) and resuspended at a concentration of 1 Â 10 6 /ml in tissue culture medium RPMI (RPMI 1640-Hepes with Glutamax-I, Gibco-BRL), supplemented (10%) with heatinactivated FCS. Intracellular IFN-g production was detected by the means of flow cytometry and enzyme-linked immunospot (Elispot) assays.
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Detection of intracellular IFN-g production by flow cytometry One million PBMCs in 100 ml of RPMI per staining condition were placed in 96-well U-bottom tissue culture plates. The cells were stimulated with CMV antigen AD-169 (BioSite, Stockholm, Sweden) at 1 mg/ml and with PepMix pp65 (JPT Peptide Technologies GmbH, Berlin, Germany) at 25 mg/ml and incubated for 18 h at 371C in 5% CO 2 . Brefeldin A (Sigma-Aldrich, St Louis, MO, USA) at 10 mg/ml was added after the first 2 h of the incubation. As positive control, cells stimulated with 0.5 mg/ml PMA (phorbol 12-myrestate 13-acetate) and 1 mg/ml ionomycin (both from Sigma-Aldrich, Steinheim, Germany) were used. The cells were permeabilized and stained with fluorochrome-labelled anti-CD3, anti-CD4, anti-CD8 and anti-IFN-g antibodies (Becton Dickinson, San Jose, CA, USA). The samples were analysed by flow cytometry using FACSCalibur (Becton Dickinson) equipment. During each analysis, 200 000 cells were collected. A level of 0.1% IFNg-producing T cells was interpreted as a positive result.
Elispot
Culture plates (96-well polyvinylidene difluoride, (Millipore Corp., Billerica, MA, USA) plates) were pre-wet with 70% EtOH, then coated (100 ml/well) with antihuman IFN-g mAb 1-D1K (Mabtech AB, Stockholm, Sweden), diluted to 15 mg/ml in sterile-filtered PBS. The plates were kept overnight at 41C. PBMCs (100 000/well) plus 1 mg/ml of AD-169 or 25 mg/ml of PepMix were incubated for 24 h at 371C in 5% CO 2 . As the positive control, cells stimulated with PHA (Sigma-Aldrich) at 1 mg/ml were used. For detection, 100 ml of biotinylated mAb (7-B6-1-biotin) and, later, streptavidine-alkaline phosphatase (both from Mabtech AB), diluted in filtered PBS with FBS (0.5%) to a concentration of 1 mg/ml, were added to each well. After washing, the cells were developed by adding 100 ml of colorimetric substrate (BCIP/NBT-plus, Mabtech AB, Stockholm, Sweden) per well and then counted in an Elispot reader. All tests were carried out in duplicate and mean values were calculated. A response was taken as positive when the number of spots in the wells with stimulated cells, after subtraction of the background (wells without peptide stimulation), was at least twofold greater than the number of background spots.
Assessment of CMV-specific immunity
One investigator (PL) interpreted the results of the CMVspecific CD4 and CD8 immune assays. The results were given to the physicians in charge of the patients as CMV-specific immunity being present (both CD4 and CD8 immunity), mixed (either CD4 or CD8 immunity) or absent.
Quantitative PCR for CMV DNA All patients were monitored weekly for quantification of CMV DNA by PCR. Real-time PCR was used on peripheral blood lymphocytes (PBLs) before October 2004 and after that time on whole blood. 11, 19 CMV disease was defined as described previously by Ljungman et al.
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Pre-emptive antiviral therapy Pre-emptive antiviral therapy with either intravenous ganciclovir or foscarnet was given within 3 months after SCT to all patients who had a viral load of 100 genome copies per 200 000 cells in PBL PCR or 1000 copies/ml in the whole blood PCR. 21, 22 Three months after SCT, patients were treated according to the study strategy. If a patient had CMV reactivation occurring 3 months after SCT, antiviral therapy was to be deferred in patients with existing CD4 and CD8 immunity unless they had severe acute GVHD requiring high-dose corticosteroids, if symptoms suggestive of CMV disease were present or if the clinician in charge felt that antiviral therapy was in the best interest of the patient. Patients with mixed or absent CMV immunity were to be treated according to the same strategy as within 3 months after SCT.
Statistics
Factors influencing the strength of the CMV-specific immune response and the effect of CMV-specific immunity on subsequent CMV DNAemia were analysed by means of t-tests. Only events occurring within 3 months after SCT were taken into account in the risk factor analyses. P-values less than 0.05 were interpreted as statistically significant.
Results
CMV DNAemia and CMV disease
Fifty-eight allogeneic SCT recipients, including sibling and unrelated donor transplants with a risk of developing of CMV infection because of donor and/or recipient CMV seropositivity, were enrolled in the present study. Thirteen patients (22.4%) have not experienced CMV reactivation, 45 patients (77.6%) have experienced CMV DNAemia, 28 patients had CMV detected only within 3 months after SCT, 15 had CMV both before and after 3 months; and two patients had CMV detected only after 3 months. Four patients (6.9%) developed CMV disease; all four had CMV GI disease. Three CMV disease episodes occurred before and one after 3 months from SCT. Thus, 17 patients of whom two had two episodes (that is 19 episodes in total) of CMV DNAemia 3 months after SCT were available for assessment of the study strategy of antiviral therapy based on immune status.
Application of study strategy
The study strategy was correctly applied in 16 of 19 episodes. Therapy was deferred in 5 of 19 episodes. None of these patients developed CMV disease. Antiviral therapy was correctly given according to the strategy in 11 of 19 episodes (in six episodes owing to lack of immunity, in three because of suspected CMV disease and in two because of severe GVHD). Two patients (three episodes) received antiviral therapy despite having T cell-specific immunity, at the discretion of the physician in charge.
Factors influencing CMV-specific immunity
At the time of sampling, all patients were 100% donor chimaeras, suggesting that the responding cells were transferred from the stem cell donors. Patients who had received a graft from a seropositive donor had stronger CD4 and CD8 CMV-specific immunity as assessed by Elispot at 3 months after SCT (Po0.01), whereas there was no effect as regards the serostatus of the patient (Figures 1a  and 1b) . No effect of the type of conditioning (reduced vs myeloablative), the use of T cell antibodies (ATG or alemtuzumab) in the conditioning regimen, the grade of acute GVHD (0-I vs II-IV), the stem cell source (PBSC vs bone marrow), the donor age or the type of donor (HLA-identical sibling vs unrelated donor) were observed.
There was no difference in either CD4 or CD8 immunity at 3 months whether or not the patients had experienced a CMV DNAemia episode within 3 months after SCT. However, there was a tendency for patients who experienced CMV DNAemia 3 months after SCT to have weaker CD8 þ T-cell immunity, as assessed by Elispot at 3 months than those who had not (P ¼ 0.06). There was no effect of CD4 immunity on the likelihood of late CMV DNAemia.
Discussion
Antiviral prophylaxis or the use of pre-emptive treatment during the first 100 days after allogeneic SCT, based on sensitive methods of virus detection, has dramatically reduced early CMV disease. 8, 9 Whereas the frequency of patients developing early CMV disease has declined to 3-6%, the risk of late CMV disease has increased over the past few years. 1, 23 Lack of CMV-specific immunity has been reported to be an important risk factor for development of late CMV infection, which might lead to longer and repeated use of antiviral drugs, and increase the risk of development of antiviral drug resistance. 24 During the last few years, techniques such as the MHC-I tetramer assay, intracellular cytokine detection by flow cytometry and Elispot have become available, allowing virus-specific immunological monitoring of SCT patients. 6, 14, 16, 25 In a previous study, we showed that immunological monitoring of CMV-specific immunity is potentially useful in assessing of functional CMV immunity in SCT patients. 17 In the present study, we looked at CMV-specific immunity 3-6 months after SCT with the aim of using the information as a decision tool for patient management. By applying the strategy, 25% of the patients who had late CMV DNAemia could be spared additional antiviral therapy without development of CMV disease. Furthermore, none of these patients needed antiviral therapy later on after SCT. Regarding the 75% of patients who received late antiviral therapy, only two of 19 could have had antiviral therapy deferred, according to the study protocol. The number of assessable episodes was low, and therefore we have to be careful about drawing conclusions that may be too strong. However, one interesting finding supporting the chosen strategy was that patients who lacked CMVspecific CD8 þ cells at 3 months were more likely to experience reactivated CMV later. It is unknown if the same strategy could be safely applied earlier after SCT, so that patients who have CMV-specific immunity and lack other risk factors of CMV disease, such as GVHD, could be spared pre-emptive therapy. We had a low frequency of grade II-IV acute GVHD in the study cohort similar to that reported previously from our centre. This might be due to our practice to treat acute GVHD grade I with corticosteroids.
We believe that the strategy of deferred antiviral therapy based on the presence of CMV-specific immune response merits further study for which a multicentre trial is needed.
We also analysed factors influencing the development of CMV-specific immunity. The only significant factor was that patients receiving grafts from CMV seronegative donors were less likely to have CMV-specific immunity at 3 months after SCT, which is in accordance with the results of some other recent studies. 17, 22, 26 We found no other factor influencing the development of CMV-specific immunity, but this might be a result of the relatively low number of patients included in the study.
In conclusion, the results of our study suggest that immunological assays used together with virological monitoring can be used to guide the use of pre-emptive antiviral therapy, thereby avoiding unnecessary treatment in a proportion of allogeneic SCT patients.
